| Updated in 12/6/2017 11:35:57 PM |
Viewed: 315 times |
(Journal Article) |
Alzheimer's & dementia (Amsterdam 6 (2017)
Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design
Wilde A
,
Maurik IS
,
Kunneman M
,
Bouwman F
,
Zwan M
ABSTRACT
The Alzheimer's biomarkers in daily practice (ABIDE) study is designed to translate knowledge on novel diagnostic tests (magnetic resonance imaging [MRI], cerebrospinal fluid [CSF], and amyloid positron emission tomography [PET]) to daily clinical practice with a focus on mild cognitive impairment (MCI). ABIDE is a 3-year project with a multifaceted design and is structured into interconnected substudies using both quantitative and qualitative research methods. Based on retrospectively available data, we develop personalized risk estimates for MCI patients. Prospectively, we collect MRI and CSF data from 200 patients from local memory clinics and amyloid PET from 500 patients in a tertiary setting, to optimize application of these tests in daily practice. Furthermore, ABIDE will develop strategies for optimal patient鈥揷linician conversations. Ultimately, this will result in a set of practical tools for clinicians to support the choice of diagnostic tests and facilitate the interpretation and communication of their results. Results will be implemented in clinical practice of local memory clinics.